Why Silymarin Has Low Bioavailability—and How Liposomal Delivery Improves Absorption

For formulation scientists, R&D directors, and brand owners developing next-generation liver health products, understanding the mechanism of liposomal silymarin is essential for informed ingredient selection and product positioning. Silymarin-the bioactive flavonolignan complex from milk thistle (Silybum marianum)-is widely recognized for its hepatoprotective, antioxidant, and anti-inflammatory properties. However, conventional silymarin extracts have consistently faced a fundamental limitation: the compound exhibits poor aqueous solubility, limited intestinal absorption, and extensive first-pass metabolism, resulting in low oral bioavailability. Active plasma concentrations of flavonolignans have been reported in the range of 50 to 300 ng/mL, with a Tmax of approximately 6–8 hours, reflecting the relatively limited systemic exposure associated with conventional silymarin formulations. Although reported oral absorption of silymarin is approximately 23%–47%, extensive first-pass metabolism further limits systemic exposure. Liposomal silymarin powder addresses these challenges through phospholipid encapsulation, offering a delivery approach designed to improve the dispersion and systemic availability of this valuable bioactive compound.

Silymarin's poor oral bioavailability is multifactorial, stemming from three primary barriers.

Barrier 1: Low Aqueous Solubility

Silymarin is a hydrophobic compound with very low water solubility. Aqueous solubility is reported at less than 50 μg/mL, which severely limits dissolution in the gastrointestinal tract. The lipophilic nature of these flavonolignans results in low solubility in water, and once absorbed, extensive first-pass metabolism further reduces its therapeutic efficacy when administered in standard formulations.

Barrier 2: Limited Intestinal Permeability

Silymarin flavonolignans exhibit limited intestinal permeability, while efflux transporters such as MRP2 and BCRP may further restrict systemic absorption. The apparent permeability coefficient is low, limiting the amount of active compound available for systemic absorption. Poor intestinal absorption, heightened metabolism in the liver, and accelerated excretion decrease silymarin concentration in the circulation and consequently at the target site.

Barrier 3: Extensive First-Pass Metabolism

Once absorbed, silymarin undergoes rapid and extensive first-pass metabolism, primarily in the intestine and liver. The clearance of silymarin involves considerable first-pass metabolism, which is largely by phase II conjugation. This metabolism is primarily mediated by UDP-glucuronosyltransferase (UGT) isoforms (mainly UGT1A1, 1A6, 1A7, 1A9, 2B7, and 2B15). Silymarin flavonolignans undergo rapid first-pass metabolism primarily by glucuronidation. Human pharmacokinetic studies have shown that glucuronidated and sulfated conjugates account for major circulating forms of silymarin flavonolignans, with approximately 55% and 28%, respectively, observed near plasma peak concentrations.

The parent compounds and their conjugates are also subject to efflux back into the intestinal lumen by transporters like MRP2 and BCRP, further limiting systemic absorption. Less than 3% of the administered dose is excreted in the urine as the unchanged drug.

The Cumulative Impact

The cumulative effect of these barriers is that conventional silymarin products deliver only a fraction of their labelled content to systemic circulation. Although gastrointestinal absorption of silymarin has been reported in the range of approximately 23%–47%, extensive first-pass metabolism and rapid elimination can substantially limit the systemic exposure of intact flavonolignans.

Liposomal delivery technology addresses the bioavailability challenges of silymarin through phospholipid encapsulation. Silymarin molecules are encapsulated within phospholipid bilayers-typically derived from non-GMO sunflower phosphatidylcholine-forming nanoscale vesicles with controlled and relatively uniform particle-size distributions.

Enhanced Solubilisation and Dispersion

Encapsulation transforms poorly soluble silymarin into a form that can be dispersed in aqueous environments. This addresses the primary barrier of low aqueous solubility, enabling more consistent dissolution in the gastrointestinal tract. Studies have shown that silymarin-loaded liposomes and polymeric micelles improve bioavailability and therapeutic efficacy.

Modification of Gastrointestinal Behaviour

The phospholipid bilayer can modify the gastrointestinal behavior of silymarin and may help improve its dispersion and protect the encapsulated compound under certain formulation conditions. Conventional liposomes have shown enhanced bioavailability compared to silymarin alone. Liposomes obtained from natural phospholipids are biocompatible and biodegradable, and can incorporate a wide range of water and lipid soluble drugs.

Potential Lymphatic Transport and Cellular Interaction

Certain lipid-based delivery systems may facilitate lymphatic transport and alter the absorption and disposition of poorly soluble compounds. Liposomal systems can interact with intestinal membranes and may alter the release, transport, and cellular uptake of encapsulated compounds.

Preclinical Evidence for Liposomal Silymarin

A study published in Pharmacological Reports (2014) developed a lecithin-based carrier system of silymarin incorporating a phytosomal-liposomal approach. The liposomal formulation yielded a three and half fold higher bioavailability of silymarin compared with silymarin suspension when evaluated in Wistar rats. The formulation showed maximum entrapment of 55% for a lecithin–cholesterol ratio of 6:1, and demonstrated better hepatoprotection efficacy (one and a half times) and better prevention of reactive oxygen species production (ten times) compared to silymarin. In in vivo models, the formulation was found more efficacious than silymarin suspension in protecting the liver against toxicity and associated inflammatory conditions.

A study published in the Journal of Agricultural and Food Chemistry (2014) prepared silymarin formulations entrapped in liposomes and ethosomes (LSM and ESM, respectively) to improve oral bioavailability and evaluate tissue distribution. Results showed that the liposomal and ethosomal encapsulated formulations of silymarin may provide more efficient tissue distribution and increased oral bioavailability, thus improving its therapeutic bioactive properties in the body.

Additional Liposomal Silymarin Research

Research on silymarin-loaded liposomes containing a bile salt prepared by supercritical fluid technology reported an optimized formulation with particle size of 160.5 nm, entrapment efficiency of 91.4%, and in vivo AUC₀₋ₜ that was 4.8-fold higher than that of silymarin powder.

These results are formulation-specific and should not be interpreted as universal performance benchmarks for all liposomal silymarin products. Commercial bioavailability should be established through product-specific pharmacokinetic studies.

For B2B buyers, liposomal silymarin powder offers commercially relevant advantages that extend beyond pharmacokinetic metrics.

Product Differentiation

In a crowded liver health market, bioavailability is a demonstrable point of differentiation. Pharmacokinetic data can provide an additional basis for product differentiation when formulation-specific evidence is available. This is particularly valuable for premium-positioned products targeting health-conscious consumers who demand science-backed formulations.

Formulation Flexibility

Liposomal silymarin is available in multiple formats to accommodate diverse finished-product requirements:

Suppliers offer various concentrations to meet specific formulation needs.

Dose Optimisation Potential

Improved bioavailability may create opportunities to explore dose optimization during formulation development, although any reduction in active ingredient dosage should be supported by product-specific pharmacokinetic and efficacy data.

Supply Chain Reliability

For procurement professionals, key considerations extend beyond the ingredient itself:

• Vertically integrated manufacturing ensures batch-to-batch consistency
• Comprehensive certifications (cGMP, ISO 22000, FSSC 22000, HACCP) provide regulatory assurance for global market access
• Documentation support (COA, TDS, SDS, stability data, particle size analysis) streamlines quality assurance and regulatory compliance

The shift from conventional to liposomal silymarin is not merely a formulation upgrade-it is a strategic decision with implications for product performance, brand positioning, and commercial success.

For finished-product manufacturers, the key benefits are:

• Credible scientific communication: Pharmacokinetic data can support product differentiation and technical communication with B2B customers
• Product differentiation: Formulation-specific pharmacokinetic data can provide an additional basis for differentiated positioning in the premium ingredient market.
• Regulatory preparedness: Comprehensive documentation packages facilitate faster market entry across multiple jurisdictions

For contract manufacturers and private-label suppliers, offering liposomal formulations expands the service portfolio and positions the company as a technology leader rather than a commodity ingredient reseller.

Conventional silymarin suffers from limited systemic bioavailability due to three fundamental barriers: low aqueous solubility, limited intestinal permeability, and extensive first-pass metabolism primarily via glucuronidation and sulfation. Although gastrointestinal absorption of silymarin has been reported in the range of approximately 23%–47%, extensive metabolism and elimination can substantially limit systemic exposure to intact flavonolignans. liposomal delivery technology addresses these limitations by encapsulating silymarin within phospholipid bilayers that can enhance solubilisation, modify gastrointestinal behaviour, and influence the release and cellular uptake of the encapsulated compound. Preclinical studies have demonstrated significant improvements in pharmacokinetic parameters-including 3.5-fold higher bioavailability for a specific liposomal formulation in Wistar rats and 4.8-fold higher AUC for a bile salt-containing liposomal formulation.

These results are formulation-specific and should not be interpreted as universal performance benchmarks for all liposomal silymarin products. For B2B buyers-formulators, R&D directors, procurement managers, and brand owners-liposomal silymarin represents not just a formulation choice, but a strategic investment in product performance and brand credibility.

Ready to evaluate liposomal silymarin for your next formulation? Our technical team is available to discuss specification requirements, provide stability data, and support your product development from concept to commercial launch.

• Request a sample for in-house testing and formulation trials
• Download the technical data package (COA, stability studies, particle size analysis)
• Inquire about custom specifications (concentration, particle size, excipient options)
• Schedule a technical consultation with our formulation scientists

[Contact our B2B team today to discuss your requirements.]

Email: liu@wellgreenxa.com

1. Frontiers in Pharmacology. Silymarin as a phytopharmaceutical agent: advances in mechanistic insights, formulation strategies, and pre-clinical applications. Front Pharmacol. 2025. doi:10.3389/fphar.2025.1711653
2. Kumar N, Rai A, Reddy ND, et al. Silymarin liposomes improves oral bioavailability of silybin besides targeting hepatocytes, and immune cells. Pharmacol Rep. 2014;66(5):788-798. doi:10.1016/j.pharep.2014.04.007
3. Chang LW, et al. Silymarin in liposomes and ethosomes: pharmacokinetics and tissue distribution in free-moving rats by high-performance liquid chromatography-tandem mass spectrometry. J Agric Food Chem. 2014;62(48):11657-11665. doi:10.1021/jf504139g
4. Yang G, et al. Enhanced oral bioavailability of silymarin using liposomes containing a bile salt: preparation by supercritical fluid technology and evaluation in vitro and in vivo. Int J Nanomedicine. 2015;10:6633-6644. doi:10.2147/IJN.S92665
5. Xie Y, Miranda SR, Hoskins JM, Hawke RL. Role of UDP-Glucuronosyltransferase 1A1 in the Metabolism and Pharmacokinetics of Silymarin Flavonolignans in Patients with HCV and NAFLD. Molecules. 2017;22(1):142. doi:10.3390/molecules22010142